Headline RoundupOctober 30th, 2020

Moderna Advances COVID-19 Vaccine Development

Summary from the AllSides News Team

Moderna executives said in a press release Thursday that the company is on track to report early data from a late-stage trial of its experimental COVID-19 coronavirus vaccine, after initial results of its 30,000 person trial come in. The company said it expects to apply for authorization from the Food and Drug Administration (FDA) in early December if all requirements are met. The FDA requires a 50 percent efficacy rate for approval, though Moderna said it wants to have at least a 75 percent efficacy rate overall. The company expects the vaccine to be widely available in 2021; Moderna stock went up by 3 percent after its announcement Thursday, and the company is already taking in $1.1 billion in deposits from countries around the globe. The story was widely covered by outlets on all sides of the political spectrum; some left-rated outlets focused on the news in the context of the Trump administration's Operation Warp Speed project.

Featured Coverage of this Story

More headline roundups

AllSides Picks

More News about Coronavirus from the Left, Center and Right

From the Left

From the Center

From the Right